Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-483"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-483"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-4842
lpv:speaker	lp:Claude Turmes2
lpv:spokenAs	member; Delegation for relations with the United States (2009-09-16--2014-06-30)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2013-06-09)3 member; ITRE (2009-07-16--2012-01-18)3 unknown; Déi Gréng - Les Verts (2009-07-14--2014-06-30)3 substitute; Delegation to the EU-Chile Joint Parliamentary Committee (2009-09-16--2012-02-05)3 substitute; IMCO (2009-07-16--2012-01-18)3 vice-chair; G/EFA (2009-07-14--2012-01-31)3 substitute; EMPL (2009-07-16--2012-01-18)3
lpv:translated text	"Mr President, medicinal products are, of course, a business worth several billions, and this was therefore a dossier which was subject to a great deal of lobbying. One very positive point in the Committee on the Internal Market and Consumer Protection is that we succeeded in keeping the internal market open. We worked on all aspects of the surveillance of adverse reactions explained by my colleagues and, above all, we managed, the pharmaceutical lobby notwithstanding, to ensure that controls during the placing on the market are not watered down and that patient information is guaranteed. In fact, one of the ideas being put around was to issue prospectuses or summaries, which would have been a very bad idea. I am sorry that one idea which I put forward in my report, the idea of also testing the therapeutic added value of new medicinal products, was not adopted. Today, we face a strategy by the major companies which, whenever a patent expires, change a few molecules and launch a massive marketing campaign. Today, many companies spend more on marketing than on research and, as a result, we have new medicinal products which cost a lot of money and have almost no added value compared with existing cheaper medicinal products. We really must examine this in detail at the next review. Our national health systems are collapsing under the cost, and every measure which can offer them relief must be taken. The fact that there is no obligation to test for therapeutic added value is a real loophole in our legislation."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph